Develops investigational medicines for serious infectious diseases and cancer, including treatments for hepatitis delta and solid tumors.
10-K for FY2025, filed Feb 23, 2026Vir Biotechnology, Inc. (including its subsidiaries, referred to as “Vir Bio,” “the Company,” “we,” “our” or “us”) is a clinical-stage…View ↗
Our clinical development pipeline consists of investigational therapies targeting hepatitis delta virus (HDV) and multiple solid tumors. In…View ↗
We are developing therapeutic candidates in HIV cure and multiple solid tumors. Our HIV broadly neutralizing antibodies (bnAbs) are being…View ↗
License and collaboration agreements are the main revenue source; partners may pay upfront, reimburse research, pay milestones, share profits, and pay royalties on sales. Research-service amounts can come in as Vir performs the work, while royalties depend on partner sales.
10-K for FY2025, filed Feb 23, 2026
10-K for FY2025, filed Feb 23, 2026
FY2025 revenue by product or service ↗$68.6M
10-K for FY2025, filed Feb 23, 2026
$68.6M ↗| Segment | Share | Revenue |
|---|---|---|
|
License and collaboration revenue
|
92% |
License and collaboration revenue, FY2025
$63.1M Sources
|
|
Grant revenue
|
3.0%
FY2022: 2.2%
|
Grant revenue, FY2025
$2M Sources
|
|
Other revenue
|
4.9% |
Other revenue, FY2025
$3.4M Sources
|
Norgine holds commercial rights to the CHD combination in Europe, Australia and New Zealand; for approved products, Vir expects to use its own resources and third-party relationships to sell and distribute.
10-K for FY2025, filed Feb 23, 2026
No. It lost $438M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Oct 14, 2026
On October 9, 2026, Vir Biotechnology, Inc. (Vir Bio) and Gilead Sciences, Inc. (Gilead) entered into a Collaboration and License Agreement…View ↗
8-K, filed Oct 1, 2026
On October 1, 2026, Vir Biotechnology, Inc. (the Company) announced that Aziz Sawaf, MBEE, MBA, CFA has been appointed as Executive Vice…View ↗
8-K, filed Jul 24, 2026
On July 20, 2026, Jason O’Byrne, MBA, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (Vir Bio), informed…View ↗
Shrinking. Revenue fell 94% in 4 years, from $1.1B in FY2021 to $68.6M in FY2025, about 50% a year.
Cancer added to the focus
The older report centered on infectious-disease treatments and prevention; the latest describes work on serious infectious diseases and cancer, including solid-tumor candidates.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 23, 2026
From marketed drug to clinical pipeline
The older report described sotrovimab as a marketed product, while the latest business overview centers on investigational hepatitis delta and solid-tumor programs.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 23, 2026Our clinical development pipeline consists of investigational therapies targeting hepatitis delta virus (HDV) and multiple solid tumors. In…View ↗
Competes with Gilead, Mirum, Bluejay Therapeutics, Huahui Health, Assembly Biosciences, Novartis, Janux, Johnson & Johnson, Regeneron, GSK, Bayer, Amgen, Merck, Pfizer, AstraZeneca, Roche, Daiichi Sankyo, Remegen, Jazz, and BioNTech
10-K for FY2025, filed Feb 23, 2026There are currently no FDA-approved treatments for CHD. Gilead’s bulevirtide is approved for use by the EMA. Gilead has refiled for…View ↗
Loading...